More than two years after the passage of the Inflation Reduction Act and the rapid implementation of the drug price negotiation program, the life sciences industry is adapting to new economic realities. Attorneys at Ropes & Gray have discussed how the law has influenced licensing strategies, specifically highlighting its impact on maximum fair prices and their economic effects on certain drugs.
As this legislation continues to shape the market, companies must reassess their strategies to remain compliant and competitive. For further insights on the ongoing impact of the drug price negotiation program, explore the discussion by attorneys in the original article on Law360.